HTR2B: A Potential Drug Target and Biomarker for Psychiatric Disorders

Target Name: HTR2B

NCBI ID: G3357

HTR2B

HTR2B: A Potential Drug Target and Biomarker for Psychiatric Disorders

Serotonin receptor 2B (HTR2B) is a G protein-coupled receptor that is expressed in various tissues, including the brain, and is involved in the regulation of mood, anxiety, and behavior. It is one of the most well-studied GPRs, with over 1,200 putative binding sites identified.1 Given its prominent role in neurotransmission, HTR2B has been identified as a potential drug target for a variety of psychiatric disorders.

HTR2B is involved in the regulation of a wide range of physiological processes, including mood regulation, anxiety, and inflammation.2 It is a key receptor for several neurotransmitters, including serotonin, dopamine, and norepinephrine.3 As such, alterations in HTR2B function have been implicated in a range of psychiatric disorders, including depression, anxiety, and psychosis.4

One of the key challenges in studying HTR2B is its complex cellular and molecular biology. While several studies have identified potential binding sites for small molecules,5-7 the precise mechanisms by which these sites contribute to HTR2B function remain poorly understood.8

Despite these challenges, research into HTR2B is ongoing, and there is growing interest in identifying potential drug targets and biomarkers for psychiatric disorders.9,10 One promising approach to studying HTR2B is the use of cell-based assays, such as patch-electrode clamp assays (PECAs) and optogenetic manipulation.11 These techniques allow researchers to study the molecular mechanisms underlying HTR2B function in a more detailed and controlled manner than is possible with cell-based assays in vitro.

In addition to its potential as a drug target, HTR2B is also a potential biomarker for psychiatric disorders. Given its involvement in the regulation of mood and behavior, changes in HTR2B function may be indicative of psychiatric distress.12 For example, individuals with major depressive disorder (MDD) have decreased levels of HTR2B in the brain,13 while individuals with schizophrenia have increased levels of HTR2B.14 These findings suggest that HTR2B may be an attractive biomarker for MDD and schizophrenia, and that targeting HTR2B with drugs that modulate its function may be a promising strategy for the development of new treatments for psychiatric disorders.

Given its potential as a drug target and biomarker, HTR2B is an attractive target for research into the treatment of psychiatric disorders. While further studies are needed to fully understand its function and potential as a drug target, the research being conducted into HTR2B is promising and holds the potential to lead to new and effective treatments for psychiatric disorders.

Protein Name: 5-hydroxytryptamine Receptor 2B

Functions: G-protein coupled receptor for 5-hydroxytryptamine (serotonin) (PubMed:8143856, PubMed:7926008, PubMed:8078486, PubMed:8882600, PubMed:18703043, PubMed:23519210). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances (PubMed:8143856, PubMed:7926008, PubMed:8078486, PubMed:12970106, PubMed:18703043, PubMed:23519210, PubMed:23519215, PubMed:24357322, PubMed:28129538). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors (PubMed:8143856, PubMed:8078486, PubMed:8882600, PubMed:23519215, PubMed:28129538). Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways (PubMed:23519215, PubMed:28129538). Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores (PubMed:8143856, PubMed:8078486, PubMed:8882600, PubMed:18703043, PubMed:23519215, PubMed:28129538). Plays a role in the regulation of dopamine and 5-hydroxytryptamine release, 5-hydroxytryptamine uptake and in the regulation of extracellular dopamine and 5-hydroxytryptamine levels, and thereby affects neural activity. May play a role in the perception of pain (By similarity). Plays a role in the regulation of behavior, including impulsive behavior (PubMed:21179162). Required for normal proliferation of embryonic cardiac myocytes and normal heart development. Protects cardiomyocytes against apoptosis. Plays a role in the adaptation of pulmonary arteries to chronic hypoxia. Plays a role in vasoconstriction. Required for normal osteoblast function and proliferation, and for maintaining normal bone density. Required for normal proliferation of the interstitial cells of Cajal in the intestine (By similarity)

The "HTR2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HTR2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets